Related Experiment Video
Updated: Aug 1, 2025

Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale
Published on: August 25, 2014
Prenatal exposure to pregabalin, birth outcomes and neurodevelopment - a population-based cohort study in four Nordic
Elena Dudukina1, Szimonetta Komjáthiné Szépligeti2, Pär Karlsson3
1Department of Clinical Epidemiology, Aarhus University and Aarhus University Hospital, Olof Palmes Allé 43-45, 8200, Aarhus N, Denmark. e.dudukina@clin.au.dk.
Insights
Prenatal exposure to pregabalin was not linked to major birth defects or developmental issues. While a slight increase in stillbirth risk was observed, it attenuated in further analysis, suggesting no significant association.
Area of Science:
- Obstetrics and Gynecology
- Pharmacology
- Developmental Pediatrics
Background:
- Pregabalin is commonly prescribed to pregnant women for conditions like epilepsy.
- The safety of prenatal pregabalin exposure regarding birth and neurodevelopmental outcomes requires further investigation.
Approach:
- Utilized population-based registries from Denmark, Finland, Norway, and Sweden (2005-2016).
- Compared pregabalin exposure against no antiepileptic drug use and against lamotrigine and duloxetine.
- Employed propensity score-adjusted meta-analyses (fixed-effect and Mantel-Haenszel).
Key Points:
- Prenatal pregabalin exposure showed no association with major congenital malformations, low birth weight, preterm birth, small for gestational age, low Apgar score, microcephaly, autism spectrum disorders, or intellectual disability.
- An initial elevated risk for stillbirth was observed (aPR 1.72), but this attenuated in meta-analysis.
- Adjusted hazard ratios for ADHD were elevated (1.29) but attenuated when using active comparators.
Conclusions:
- Prenatal pregabalin exposure is not significantly associated with most adverse birth or postnatal neurodevelopmental outcomes.
- Increased risks for major congenital malformations and ADHD greater than 1.8 were unlikely.
- Findings suggest a generally favorable safety profile for pregabalin during pregnancy, though further research may be warranted for specific outcomes like stillbirth.
Introduction:
Pregabalin is an antiepileptic drug frequently prescribed to pregnant women. Risks of adverse birth and postnatal neurodevelopmental outcomes following prenatal exposure to pregabalin are uncertain.
Objective:
To investigate the association between prenatal exposure to pregabalin and the risks of adverse birth and postnatal neurodevelopmental outcomes.
Methods:
This study was conducted using population-based registries in Denmark, Finland, Norway, and Sweden (2005-2016). We compared pregabalin exposure against no exposure to antiepileptics and against active comparators lamotrigine and duloxetine. We obtained pooled propensity score-adjusted estimates of association using fixed-effect and Mantel-Haenszel (MH) meta-analyses.
Results:
The total number of pregabalin-exposed births was 325/666,139 (0.05%) in Denmark, 965/643,088 (0.15%) in Finland, 307/657,451 (0.05%) in Norway, and 1275/1,152,002 (0.11%) in Sweden. The adjusted prevalence ratios (aPRs) with 95% confidence interval (CI) following pregabalin exposure versus no exposure were 1.14 (0.98-1.34) for major congenital malformations and 1.72 (1.02-2.91) for stillbirth, which attenuated to 1.25 (0.74-2.11) in MH meta-analysis. For the remaining birth outcomes, the aPRs were close to or attenuated toward unity in analyses using active comparators. Adjusted hazard ratios (95% CI) contrasting prenatal pregabalin exposure versus no exposure were 1.29 (1.03-1.63) for ADHD and attenuated when using active comparators, 0.98 (0.67-1.42) for autism spectrum disorders, and 1.00 (0.78-1.29) for intellectual disability.
Conclusions:
Prenatal exposure to pregabalin was not associated with low birth weight, preterm birth, small for gestational age, low Apgar score, microcephaly, autism spectrum disorders, or intellectual disability. On the basis of the upper value of the 95% confidence interval, increased risks greater than 1.8 were unlikely for any major congenital malformation and ADHD. For stillbirth and most groups of specific major congenital malformations, the estimates attenuated in MH meta-analysis.
More Related Videos
05:13Preclinical Model of Prenatal Delta-9-Tetrahydrocannabinol Exposure to Assess Its Impact on Neurodevelopmental Outcomes
Published on: February 28, 2025
07:36Modeling Encephalopathy of Prematurity Using Prenatal Hypoxia-ischemia with Intra-amniotic Lipopolysaccharide in Rats
Published on: November 20, 2015
Related Concept Videos
Teratogenicity
Factors Affecting Drug Response: Overview